查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肺动脉高压市场、份额、规模、趋势、产业分析报告：按类型、药物类别、给药途径、地区、细分市场预测，2023-2032 年
市场调查报告书
商品编码
1421703

肺动脉高压市场、份额、规模、趋势、产业分析报告：按类型、药物类别、给药途径、地区、细分市场预测，2023-2032 年

Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球肺动脉高压市场规模预计将达到 113.5 亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

由于老年人口越来越容易受到此类健康状况的影响，心血管疾病和肺部疾病的盛行率不断增加，预计将在未来几年推动肺动脉高压(PAH) 市场的发展。预计将推动肺动脉高压(PAH) 市场的扩张。 此外，过度饮酒、久坐、不健康饮食等不良生活习惯也会增加高血压、高血脂的风险。 再加上新的孤儿药和技术先进的肺动脉高压治疗设备的推出、公众对肺动脉高压可用治疗方案的认识的提高以及医疗基础设施的改善，预计将刺激肺动脉高压的进一步增长高血压（PAH）市场。 然而，严格的药品监管对未来市场成长构成挑战。

PAH 的症状各不相同，包括气短、疲劳、胸痛、头晕、昏厥以及脚、腿或胃肿胀。 这些症状随着时间的推移而进展，并对个人的生活品质产生重大影响。 PAH 是一种进行性疾病，可导致右心衰竭、心律不整和肺血栓形成等併发症，严重时可导致死亡。 因此，早期诊断和治疗对于有效控制疾病起着关键作用。 由肺科医生、心臟科医生和其他专家组成的专业医疗团队的定期监测对于 PAH 患者至关重要。 他们可以监督您的医疗状况，进行必要的药物调整，并提供重要的支援。 此外，也建议改变生活方式，例如定期运动、保持均衡饮食、避免吸烟和避免呼吸道刺激，以促进有效的疾病管理。

此外，国家医学图书馆 2021 年 6 月发表的一项研究强调了冠状动脉疾病 (CAD) 对全球健康的重大影响。 光是 CAD 每年就导致约 61 万人死亡，占估计死亡人数的四分之一，是美国的第一大死因。 随着 CAD 发病率的增加，对有效的肺动脉高压治疗设备的需求不断增长，以满足这一紧迫的医疗需求。 因此，预计该因素将在预测期内推动对肺动脉高压的需求。

肺动脉高压市场报告亮点

2022 年，由于强劲的需求和不断扩大的应用，前列环素和前列环素类似物领域占据了市场上最大的收入份额。 此外，SGC 刺激器领域预计成长最快，复合年增长率超过 5%。 SGC 刺激剂有望增强 NO-sGC 讯号传导并最大化 sGC 活化。

在预测期内，口服药物细分市场占据主导地位，这主要是由于治疗肺动脉高压的口服製剂的供应不断增加以及患者对口服给药的偏好。 口服 PAH 治疗的着名例子包括 Letairis、Adcirca、Opsumit 和 Revatio。

2022年，北美引领全球市场，主要得益于美国和加拿大成熟的医疗基础设施，有利于获得先进的治疗。 此外，意识的提高、高诊断率和政府支持措施也促进了该地区的市场成长。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球肺动脉高压市场洞察

  • 肺动脉高压市场－给药途径概览
  • 肺动脉高压市场动态
    • 推动者和机会
      • 肺动脉高压 (PAH) 病例推动市场成长
      • 可溶性鸟甘酸环化□ (SGC) 刺激剂的进展
    • 抑制因素和挑战
      • 重要专利到期
  • PESTEL 分析
  • 肺动脉高压市场的给药途径趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第 5 章全球肺动脉高压市场（依药物类别）

  • 主要发现
  • 简介
  • PDE-5抑制剂
  • 前列环素和前列环素类似物
  • SGC 刺激器
  • 内皮素受体拮抗剂（ERA）

第 6 章全球肺动脉高压市场（按类型）

  • 主要发现
  • 简介
  • 通用
  • 品牌

第 7 章全球肺动脉高血压市场（依给药途径）

  • 主要发现
  • 简介
  • 静脉/皮下
  • 用于吸入
  • 口头

第 8 章按地区划分的全球肺动脉高压市场

  • 主要发现
  • 简介
    • 肺动脉高压市场评估，地区，2019-2032
  • 肺动脉高压市场 - 北美
    • 北美：肺动脉高压市场，依药物类别，2019-2032 年
    • 北美：2019-2032 年肺动脉高压市场（依给药途径）
    • 北美：肺动脉高压市场，依类型，2019-2032 年
    • 肺动脉高压市场 - 美国
    • 肺动脉高压市场 - 加拿大
  • 肺动脉高压市场 - 欧洲
    • 欧洲：肺动脉高压市场，依药物类别，2019-2032 年
    • 欧洲：2019-2032 年肺动脉高压市场（依给药途径）
    • 欧洲：2019-2032 年肺动脉高压市场（按类型）
    • 肺动脉高压市场 - 英国
    • 肺动脉高压市场 - 法国
    • 肺动脉高压市场 - 德国
    • 肺动脉高压市场 - 义大利
    • 肺动脉高压市场 - 西班牙
    • 肺动脉高压市场 - 荷兰
    • 肺动脉高压市场 - 俄罗斯
  • 肺动脉高压市场 - 亚太地区
    • 亚太地区：肺动脉高压市场，依药物类别，2019-2032 年
    • 亚太地区：2019-2032 年肺动脉高压市场（依给药途径）
    • 亚太地区：肺动脉高压市场，依类型，2019-2032 年
    • 肺动脉高压市场 - 中国
    • 肺动脉高压市场 - 印度
    • 肺动脉高压市场 - 马来西亚
    • 肺动脉高压市场 - 日本
    • 肺动脉高压市场 - 印尼
    • 肺动脉高压市场 - 韩国
  • 肺动脉高压市场 - 中东和非洲
    • 中东和非洲：2019-2032 年肺动脉高压市场（依药物类别）
    • 中东和非洲：2019-2032 年肺动脉高压市场（依给药途径）
    • 中东和非洲：2019-2032 年肺动脉高压市场（按类型）
    • 肺动脉高压市场 - 沙乌地阿拉伯
    • 肺动脉高压市场 - 阿拉伯联合大公国
    • 肺动脉高压市场 - 以色列
    • 肺动脉高压市场 - 南非
  • 肺动脉高压市场 - 拉丁美洲
    • 拉丁美洲：肺动脉高压市场，依药物类别，2019-2032 年
    • 拉丁美洲：2019-2032 年肺动脉高压市场（依给药途径）
    • 拉丁美洲：肺动脉高压市场，按类型，2019-2032 年
    • 肺动脉高压市场 - 墨西哥
    • 肺动脉高压市场 - 巴西
    • 肺动脉高压市场 - 阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • Bayer
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Sandoz Inc.（Novartis）
  • Sun Pharmaceutical Industries, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Viatris Inc.
Product Code: PM4051

The global pulmonary arterial hypertension market size is expected to reach USD 11.35 billion by 2032, according to a new study by Polaris Market Research. The report "Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of cardiovascular and pulmonary disorders, driven by a growing elderly population susceptible to such health conditions, is poised to drive the pulmonary arterial hypertension (PAH) market's expansion in the forthcoming years. Moreover, lifestyle modifications, such as excessive alcohol consumption, sedentary behavior, and unhealthy dietary habits, have heightened the risk of hypertension and high blood pressure. This, combined with the introduction of novel orphan drugs and technologically advanced treatment devices for pulmonary arterial hypertension (PAH), increased awareness among the public regarding available treatment options for PAH, and improved healthcare infrastructure, is expected to fuel further the growth of the pulmonary arterial hypertension (PAH) market. However, stringent drug regulations pose a challenge to the market's growth in the years ahead.

Symptoms of PAH can exhibit variability and may encompass shortness of breath, fatigue, chest pain, dizziness, fainting, and swelling in the feet, legs, and stomach. Over time, these symptoms can progress, significantly impacting an individual's quality of life. PAH is a progressive ailment that may lead to complications, including right-sided heart failure, arrhythmias, lung blood clots, and, in severe instances, mortality. Therefore, early diagnosis and treatment play a vital role in effectively managing the condition. Regular monitoring by a specialized healthcare team comprising pulmonologists, cardiologists, and other experts is essential for individuals with PAH. They can oversee the condition, make necessary medication adjustments, and provide vital support. Furthermore, lifestyle changes like regular exercise, maintaining a balanced diet, and avoiding smoking and respiratory irritants may be advised to facilitate effective condition management.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Pulmonary Arterial Hypertension devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Pulmonary Arterial Hypertensions throughout the forecast period.

Pulmonary Arterial Hypertension Market Report Highlights

In 2022, the Prostacyclin and Prostacyclin Analogs segment claimed the largest share of revenue in the market, attributed to robust demand and expanding applications. Additionally, the SGC stimulators segment is expected to exhibit the swiftest growth, featuring a CAGR surpassing 5%. SGC stimulators hold promise for enhancing NO-sGC signaling and maximizing sGC activation.

During the forecast period, the Oral segment dominated the market, primarily due to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for oral administration. Notable examples of oral PAH drugs comprise Letairis, Adcirca, Opsumit, and Revatio.

In 2022, North America led the global market, primarily driven by its well-established healthcare infrastructure in the United States and Canada, facilitating advanced therapeutic access. Moreover, increased awareness, a high diagnosis rate, and government support initiatives contribute to the market's growth in this region.

The global key market players include: Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Viatris Inc.

Polaris Market Research has segmented the Pulmonary Arterial Hypertension market report based on type, drug class, route of administration, and region:

Pulmonary Arterial Hypertension, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Generics
  • Branded

Pulmonary Arterial Hypertension, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • Endothelin Receptor Antagonists (ERAs)

Pulmonary Arterial Hypertension, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Intravenous/ subcutaneous
  • Inhalational
  • Oral

Pulmonary Arterial Hypertension, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pulmonary Arterial Hypertension Market Insights

  • 4.1. Pulmonary Arterial Hypertension Market - Route of Administration Snapshot
  • 4.2. Pulmonary Arterial Hypertension Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Cases of Pulmonary Arterial Hypertension (PAH) Facilitate Market Growth
      • 4.2.1.2. Advancement of soluble guanylate cyclase (SGC)-stimulating drugs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Expiration of critical patents
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Pulmonary Arterial Hypertension Market Route of Administration Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pulmonary Arterial Hypertension Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. PDE-5 Inhibitors
    • 5.3.1. Global Pulmonary Arterial Hypertension Market, by PDE-5 Inhibitors, by Region, 2019-2032 (USD Billion)
  • 5.4. Prostacyclin and Prostacyclin Analogs
    • 5.4.1. Global Pulmonary Arterial Hypertension Market, by Prostacyclin and Prostacyclin Analogs, by Region, 2019-2032 (USD Billion)
  • 5.5. SGC Stimulators
    • 5.5.1. Global Pulmonary Arterial Hypertension Market, by SGC Stimulators, by Region, 2019-2032 (USD Billion)
  • 5.6. Endothelin Receptor Antagonists (ERAs)
    • 5.6.1. Global Pulmonary Arterial Hypertension Market, by Endothelin Receptor Antagonists (ERAs), by Region, 2019-2032 (USD Billion)

6. Global Pulmonary Arterial Hypertension Market, by Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 6.3. Generics
    • 6.3.1. Global Pulmonary Arterial Hypertension Market, by Generics, by Region, 2019-2032 (USD Billion)
  • 6.4. Branded
    • 6.4.1. Global Pulmonary Arterial Hypertension Market, by Branded, by Region, 2019-2032 (USD Billion)

7. Global Pulmonary Arterial Hypertension Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 7.3. Intravenous/ subcutaneous
    • 7.3.1. Global Pulmonary Arterial Hypertension Market, by Intravenous/ subcutaneous, By Region, 2019-2032 (USD Billion)
  • 7.4. Inhalational
    • 7.4.1. Global Pulmonary Arterial Hypertension Market, by Inhalational, By Region, 2019-2032 (USD Billion)
  • 7.5. Oral
    • 7.5.1. Global Pulmonary Arterial Hypertension Market, by Oral, By Region, 2019-2032 (USD Billion)

8. Global Pulmonary Arterial Hypertension Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Pulmonary Arterial Hypertension Market - North America
    • 8.3.1. North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.3.3. North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.3.4. Pulmonary Arterial Hypertension Market - U.S.
      • 8.3.4.1. U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.3.5. Pulmonary Arterial Hypertension Market - Canada
      • 8.3.5.1. Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4. Pulmonary Arterial Hypertension Market - Europe
    • 8.4.1. Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.4. Pulmonary Arterial Hypertension Market - UK
      • 8.4.4.1. UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.5. Pulmonary Arterial Hypertension Market - France
      • 8.4.5.1. France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.6. Pulmonary Arterial Hypertension Market - Germany
      • 8.4.6.1. Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.7. Pulmonary Arterial Hypertension Market - Italy
      • 8.4.7.1. Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.8. Pulmonary Arterial Hypertension Market - Spain
      • 8.4.8.1. Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.9. Pulmonary Arterial Hypertension Market - Netherlands
      • 8.4.9.1. Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.10. Pulmonary Arterial Hypertension Market - Russia
      • 8.4.10.1. Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5. Pulmonary Arterial Hypertension Market - Asia Pacific
    • 8.5.1. Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.4. Pulmonary Arterial Hypertension Market - China
      • 8.5.4.1. China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.5. Pulmonary Arterial Hypertension Market - India
      • 8.5.5.1. India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.6. Pulmonary Arterial Hypertension Market - Malaysia
      • 8.5.6.1. Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.7. Pulmonary Arterial Hypertension Market - Japan
      • 8.5.7.1. Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.8. Pulmonary Arterial Hypertension Market - Indonesia
      • 8.5.8.1. Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.9. Pulmonary Arterial Hypertension Market - South Korea
      • 8.5.9.1. South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.6. Pulmonary Arterial Hypertension Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.4. Pulmonary Arterial Hypertension Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.5. Pulmonary Arterial Hypertension Market - UAE
      • 8.6.5.1. UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.6. Pulmonary Arterial Hypertension Market - Israel
      • 8.6.6.1. Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.7. Pulmonary Arterial Hypertension Market - South Africa
      • 8.6.7.1. South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.7. Pulmonary Arterial Hypertension Market - Latin America
    • 8.7.1. Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.4. Pulmonary Arterial Hypertension Market - Mexico
      • 8.7.4.1. Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.5. Pulmonary Arterial Hypertension Market - Brazil
      • 8.7.5.1. Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.6. Pulmonary Arterial Hypertension Market - Argentina
      • 8.7.6.1. Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Bayer
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Gilead Sciences, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. GlaxoSmithKline
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Johnson & Johnson
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Lupin Pharmaceuticals, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sandoz Inc. (Novartis)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Sun Pharmaceutical Industries, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Teva Pharmaceutical Industries Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. United Therapeutics Corporation
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Viatris Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 4 Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 7 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 8 U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 11 Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 14 Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 19 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 20 France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 22 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 23 Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 26 Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 35 Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 43 China: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 44 India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 46 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 50 Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 56 South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 65 UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 68 Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 71 South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 74 Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 77 Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 80 Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 83 Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Pulmonary Arterial Hypertension Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Pulmonary Arterial Hypertension Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Route of Administration
  • Figure 11. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2022 & 2032 (USD Billion)
  • Figure 12. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Pulmonary Arterial Hypertension Market